国产a级特黄的片子,精品香蕉一区二区三区,亚洲精品99久久久久中文字幕,无码精品A∨在线观看无广告

Stock(600222)Hot line:010-61006450

News

Understand the latest news of Leadingpharm

Dr. Zhu Haobin from Leadingpharm CXO · Deep Blue Ocean was invited to attend the CBA China Annual Conference: Exploring the Path of Pharmaceutical Innovation and Adaptation Together

Release time:2024-07-08
On June 28-29, 2024, Dr. Zhu Haobin, Vice General Manager of Leadingpharm CXO · Deep Blue Ocean, was invited to attend the first CBA China Annual Meeting of the American Chinese Biomedical Technology Association at the Suzhou International Expo Center. At this grand gathering of global pharmaceutical elites, Dr. Zhu shared his profound insights on the challenges and opportunities of the pharmaceutical industry.

The CBA China Annual Conference not only gathered over 1100 top experts from different fields, but also attracted over 20000 delegates to discuss the future of the biopharmaceutical industry together. Dr. Zhu's speech at the annual meeting presented unique insights and coping strategies in response to external driving forces and challenges faced by medical work.

?  Facing challenges and adapting to changes:

Against the backdrop of economic cycle fluctuations and demographic changes, the pharmaceutical industry must constantly adapt to market demand and update clinical diagnosis and treatment standards. We have witnessed the transition from traditional medicine to targeted therapy, and the evolution from monotherapy to personalized medicine. Dr. Zhu emphasized that the pharmaceutical industry is facing unprecedented challenges under the combined effects of macroeconomic factors such as economic cycles, demographic changes, and geopolitics. This requires the sponsor and project outsourcing agency to quickly adapt to changes in the industry environment and policy orientation during research and implementation.
 

?  How external pressures can have a downward impact on clinical practice and sponsors:

The applicant is facing unprecedented pressure in project initiation decisions and portfolio strategies. How to ensure the stability of the company's cash flow while ensuring project progress has become a challenge we must face.

Dr. Zhu used popular anti-tumor targets such as small molecules and bispecific drugs as examples to explore changes in competitor data and clinical best practices, how they affect project approval, indication selection and prioritization, and how dynamic adjustments can be made. He emphasized that under the new normal, improving clinical prediction and risk awareness has become a higher requirement for medical staff.

At different stages of clinical research and development, Dr. Zhu used seven vivid cases in the fields of chronic diseases, medical aesthetics, rare diseases, and cell/gene therapy to illustrate how New Leading Medicine actively optimizes trial design to assist applicants in achieving cost reduction and efficiency improvement. He emphasized that under the new normal, applicants need CRO to provide more flexible and professional support from project evaluation to NDA stage. This support is not only based on the professionalism of CRO, but also requires medical personnel to have a broader perspective and more proactive thinking ability.
 

?  Looking to the future, and keep learning

Dr. Zhu pointed out that the widespread application of main trials, platforms, umbrella and basket trials, as well as the precision of indication design, are reshaping the face of clinical research. The discovery of biomarkers not only provides strong evidence for clinical mechanisms, but also significantly enhances the possibility of the project entering the next stage, laying a solid foundation for the success of phase III clinical trials. The support of real-world data provides more comprehensive and in-depth evidence for drug approval, accelerating the process of new drug launch.

The breakthrough application of artificial intelligence has not only achieved significant results in auxiliary diagnosis, disease assessment, surgical assistance, drug development, patient monitoring and management, but also demonstrated its unique value in the field of imaging evaluation. The innovative application of digital experiments, such as preclinical organs, digital human physiological/disease models, and pharmacological models, is effectively eliminating gray areas in AE/SAE judgments and improving the accuracy and safety of clinical trials.

However, the accompanying question is how professionals in the current field will adapt to this change? How will they find their place in this transformation?

Faced with the rapid changes in the pharmaceutical industry, Dr. Zhu believes that professionals need to continue learning, have an open mind, and collaborate across industries. The future of the pharmaceutical industry is full of brightness, but there are also challenges. Dr. Zhu calls on colleagues in the industry to work together and embrace a new chapter in the pharmaceutical industry with an open mind and innovative spirit, contributing to the cause of human health.

 

轉載聲明:未經本網或本網權利人授權,不得轉載、摘編或利用其他方式使用上述作品。已經本網或本網權利人授權使用作品的,應在授權范圍內使用,并注明“來源:新領先醫(yī)藥科技”。

Recommend

久久久精品456亚洲影院| 吸咬奶头狂揉60分钟视频| 国内精品伊人久久久久777| 久久人人做人人妻人人玩精品VA| 免费无码VA一区二区三区| 久久久久精品久久九九| 久久超乳爆乳中文字幕| 欧美激情a片久久久久久| 精品国产一区二区三区2021| 国产精品久久久久9999无码| av国産精品毛片一区二区小说| 国产av网站| 无码人妻精品一区二区三区蜜桃| 强伦姧人妻波多野洁衣| 久久国产精品偷任你爽任你a| 国产精品揄拍100视频| 色狠狠av一区二区三区| 高潮毛片无遮挡高清免费视频| 大陆三级经典三级在线| jizz国产精品网站| 国产处破苞无码精品| 国产50部艳色禁片无码| 人妻无奈被迫屈辱1-9| 自拍偷在线精品自拍偷无码专区| 国产综合久久久久久精品| 无码免费一区二区三区免费播放| 亚洲xxxx做受欧美| 久久精品亚洲av无码四区| 97亚洲狠狠色综合久久久久| 小箩莉末发育娇小性色xxxx| 97无码欧美熟妇人妻蜜桃天美| 无码丰满少妇2在线观看| 国产在线拍揄自揄拍无码视频 | 亚洲av无码精品色午夜| 国产69精品久久久久9999不卡| 欧美肥妇BWBWBWBXX| 久久久精品国产sm调教网站| 丰满多毛的大隂户毛茸茸| 丝袜灬啊灬快灬高潮了AV| 久久久久久亚洲精品中文字幕| 亚洲成a人片在线观看中文|